Clinical Trial: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557420) titled 'Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)' on April 23.

Brief Summary: The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).

Study Start Date: Aug. 31, 2026

Study Type: INTERVENTIONAL

Condition: NMOSD Neuromyelitis Optica Spectrum Disorder

Intervention: DRUG: Ravulizumab

Participants...